Seebri Breezhaler 44 micrograms inhalation powder (hard capsule)

Spain
Brand name Seebri Breezhaler 44 micrograms inhalation powder (hard capsule)
Form powder for inhalation, hard capsule
Active substance / Dosage
Prescription type Prescription Only Medicine
Registration number 12778003
Seebri Breezhaler 44 micrograms inhalation powder (hard capsule) powder for inhalation, hard capsule

Package leaflet: Information for the user

Introduction

Package leaflet: information for the user

Seebri Breezhaler 44 micrograms powder for inhalation (hard capsule)

glycopyrronium
(as glycopyrronium bromide)

Read all of this leaflet carefully before you start using this medicine, because it contains important information for you.

  • Keep this leaflet, as you may need to read it again.
  • If you have any questions, ask your doctor, pharmacist, or nurse.
  • This medicine has been prescribed for you only, and you should not give it to other people, even if they have the same symptoms as you, because it may harm them.
  • If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if they are side effects not listed in this leaflet. See section 4.

Contents of the leaflet

  1. What Seebri Breezhaler is and what it is used for
  2. What you need to know before using Seebri Breezhaler
  3. How to use Seebri Breezhaler
  4. Possible side effects
  5. How to store Seebri Breezhaler
  6. Contents of the pack and other information

1. What Seebri Breezhaler is and what it is used for

What Seebri Breezhaler is

This medicine contains an active substance called glycopyrronium bromide, which belongs to a class of medicines known as bronchodilators.

What Seebri Breezhaler is used for

This medicine is used to make breathing easier in adult patients who have difficulty breathing due to a lung disease called chronic obstructive pulmonary disease (COPD).

In COPD, the muscles around the airways tighten, making it difficult to breathe. This medicine blocks the tightening of these muscles in the lungs, helping air to flow in and out more easily.

If you use this medicine once daily, it will help reduce the effects of COPD in your daily life.

2. What you need to know before using Seebri Breezhaler

Do not use Seebri Breezhaler

  • if you are allergic to glycopyrronium bromide or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Talk to your doctor before starting to use Seebri Breezhaler if you have any of the following conditions:

  • if you have kidney problems.
  • if you have a type of eye disorder known as narrow-angle glaucoma.
  • if you have difficulty urinating.

While being treated with Seebri Breezhaler, stop using this medicine and contact your doctor immediately if:

  • you experience chest tightness, cough, wheezing, or difficulty breathing immediately after using Seebri Breezhaler (signs of bronchospasm).
  • you have trouble breathing or swallowing, swelling of the tongue, lips, or face, skin rash, itching, or hives (signs of an allergic reaction).
  • you notice eye pain or discomfort, temporary blurred vision, visual halos, or colored images, along with redness of the eyes. These may be signs of an acute attack of narrow-angle glaucoma.

Seebri Breezhaler is used as a maintenance treatment for your COPD. Do not use this medicine to treat a sudden attack of shortness of breath or wheezing (whistling sounds when breathing).

Children and adolescents

Do not give this medicine to children or adolescents under 18 years of age.

Other medicines and Seebri Breezhaler

Tell your doctor or pharmacist if you are taking, have recently taken, or might need to take any other medicines. This includes medicines similar to Seebri Breezhaler used for your lung disease, such as ipratropium, oxitropium, or tiotropium (also known as anticholinergics).

No specific adverse effects have been reported when Seebri Breezhaler has been administered together with other medicines used to treat COPD, such as rescue inhalers (e.g., salbutamol), methylxanthines (e.g., theophylline), and/or oral and inhaled steroids (e.g., prednisolone).

Pregnancy, breast-feeding, and fertility

If you are pregnant or breast-feeding, think you may be pregnant, or are planning to become pregnant, consult your doctor or pharmacist before using this medicine.

There is no data available on the use of this medicine in pregnant women, and it is unknown whether the active ingredient passes into breast milk.

Driving and using machines

This medicine is unlikely to affect your ability to drive or operate machinery.

Seebri Breezhaler contains lactose

This medicine contains lactose. If your doctor has informed you of an intolerance to certain sugars, consult with him before taking this medicine.

3. How to use Seebri Breezhaler

Follow exactly the instructions for administering this medicine as given by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.

Amount of Seebri Breezhaler to use

The usual dose is to inhale the contents of one capsule each day.

You only need to inhale the medicine once a day, as the effect of this medicine lasts for 24 hours.

Do not use more than the dose indicated by your doctor.

Elderly patients

If you are 75 years of age or older, you can use this medicine at the same dose as other adults.

When to inhale Seebri Breezhaler

Use this medicine at the same time each day. This will help you remember to take it.

You may inhale this medicine at any time before or after food or drinks.

How to inhale Seebri Breezhaler

  • This pack contains an inhaler and capsules (in blisters) containing the medicine as a powder for inhalation. Use the capsules only with the inhaler provided in this pack (Seebri Breezhaler inhaler). The capsules should remain in the blister until you are ready to use them.
  • Do not push the capsule through the foil.
  • When starting a new pack, use the new Seebri Breezhaler inhaler provided in the pack.
  • Dispose of the inhaler from each pack once all capsules have been used.
  • Do not swallow the capsules.
  • For more information on how to use the inhaler, please read the instructions at the end of this leaflet.

If you use more Seebri Breezhaler than you should

If you have inhaled too much of this medicine or if someone accidentally uses your capsules, inform your doctor immediately or go to the nearest emergency department. Show the Seebri Breezhaler pack. Medical attention may be required.

If you forget to use Seebri Breezhaler

If you forget to inhale a dose, inhale it as soon as possible. However, do not inhale two doses on the same day. Then inhale the next dose at your usual time.

How long you should continue treatment with Seebri Breezhaler

  • Continue using this medicine for as long as your doctor tells you to.
  • COPD is a long-term condition and you must use this medicine every day, not only when you have breathing problems or other symptoms of COPD.

Consult your doctor or pharmacist if you have any questions about how long you should continue treatment with this medicine.

If you have any further questions about the use of this medicine, ask your doctor, pharmacist, or nurse.

4. Possible adverse effects

Like all medicines, this medicine can cause adverse effects, although not everyone will experience them.

Some adverse effects may be serious but are uncommon

(may affect up to 1 in 100 patients)

  • Irregular heartbeat
  • High blood sugar level (hyperglycaemia: typical symptoms include excessive thirst or hunger and frequent urination)
  • Skin rash, itching, hives, difficulty breathing or swallowing, dizziness (possible signs of allergic reaction)
  • Swelling, mainly of the tongue, lips, face or throat (possible signs of angioedema)

If you experience any of these adverse effects, inform your doctor immediately.

Some adverse effects may be serious but their frequency is unknown

(frequency cannot be estimated from the available data)

  • Difficulty breathing with wheezing (whistling sounds when breathing) or cough (signs of paradoxical bronchospasm)

Some adverse effects are common

(may affect up to 1 in 10 patients)

  • Dry mouth
  • Difficulty sleeping
  • Runny or stuffy nose, sneezing, sore throat
  • Diarrhoea or abdominal pain
  • Musculoskeletal pain

Some adverse effects are uncommon

(may affect up to 1 in 100 patients)

  • Difficulty and pain when urinating
  • Painful and frequent urination
  • Palpitations
  • Skin rash
  • Loss of sensation
  • Cough with sputum
  • Dental caries
  • Feeling of pain or pressure in the cheeks and forehead
  • Nosebleeds
  • Pain in arms or legs
  • Pain in muscles, bones or joints of the chest
  • Stomach discomfort after meals
  • Sore throat
  • Fatigue
  • Weakness
  • Itching
  • Voice alteration (hoarseness)
  • Nausea
  • Vomiting

Some patients over 75 years of age experienced headache (commonly) and urinary tract infection (commonly).

Reporting of adverse effects

If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect not listed in this leaflet. You can also report them directly through the national reporting system included in Appendix V. By reporting adverse effects, you can help provide more information on the safety of this medicine.

5. Storage of Seebri Breezhaler

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and on the blister after «CAD»/«EXP». The expiry date refers to the last day of the month indicated.

Do not store above 25°C.

Keep the capsules in the original blister to protect them from moisture. Remove them from the blister immediately before use.

The inhaler from each package should be discarded once all capsules have been used.

Do not use this medicine if you notice that the packaging is damaged or shows signs of deterioration.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of any unused medicines and their packaging. This will help protect the environment.

6. Contents of the pack and other information

Composition of Seebri Breezhaler

  • The active substance is glycopyrronium bromide. Each capsule contains 63 micrograms of glycopyrronium bromide (equivalent to 50 micrograms of glycopyrronium). The delivered dose (the dose released by the mouthpiece of the inhaler) is equivalent to 44 micrograms of glycopyrronium.
  • The other components of the inhalation powder are lactose monohydrate and magnesium stearate.

Appearance of Seebri Breezhaler and contents of the pack

Seebri Breezhaler 44 microgram powder for inhalation hard capsules are transparent orange-coloured and contain a white powder. They have the product code "GPL50" printed in black above a black line and the company logo () printed in black below the line.

Each pack contains a device known as an inhaler, together with capsules in blisters. Each blister strip contains 6 or 10 hard capsules.

The following pack sizes are available:

Packs containing 6 x 1, 10 x 1, 12 x 1 or 30 x 1 hard capsules, together with one inhaler.

Multiple pack containing 90 (3 packs of 30 x 1) hard capsules and 3 inhalers.

Multiple pack containing 96 (4 packs of 24 x 1) hard capsules and 4 inhalers.

Multiple pack containing 150 (15 packs of 10 x 1) hard capsules and 15 inhalers.

Multiple pack containing 150 (25 packs of 6 x 1) hard capsules and 25 inhalers.

Only some pack sizes may be marketed.

Marketing Authorization Holder

Novartis Europharm Limited
Vista Building
Elm Park, Merrion Road
Dublin 4
Ireland

Manufacturer

Novartis Farmacéutica S.A.
Gran Via de les Corts Catalanes, 764
08013 Barcelona
Spain

Novartis Pharma GmbH
Roonstraße 25
D-90429 Nuremberg
Germany

For further information about this medicine, please contact the local representative of the Marketing Authorization Holder:

Belgium/Belgium/Belgium

Novartis Pharma N.V.

Tel/Tel: +32 2 246 16 11

Lithuania

SIA Novartis Baltics Lithuania Branch

Tel: +370 5 269 16 50

Text in Cyrillic and Latin characters with the words България, Novartis Bulgaria EOOD and the phone number +359 2 489 98 28

Luxembourg/Luxembourg

Novartis Pharma N.V.

Tel/Tel: +32 2 246 16 11

Czech Republic

Novartis s.r.o.

Tel: +420 225 775 111

Hungary

Novartis Hungária Kft.

Tel.: +36 1 457 65 00

Denmark

Novartis Healthcare A/S

Tlf: +45 39 16 84 00

Malta

Novartis Pharma Services Inc.

Tel: +356 2122 2872

Germany

Novartis Pharma GmbH

Tel: +49 911 273 0

Netherlands

Novartis Pharma B.V.

Tel: +31 88 04 52 111

Estonia

SIA Novartis Baltics Estonia Branch

Tel: +372 66 30 810

Norway

Novartis Norge AS

Tlf: +47 23 05 20 00

Greece

Novartis (Hellas) S.A.

Tel: +30 210 281 17 12

Austria

Novartis Pharma GmbH

Tel: +43 1 86 6570

Spain

Novartis Farmacéutica, S.A.

Tel: +34 93 306 42 00

Poland

Novartis Poland Sp. z o.o.

Tel.: +48 22 375 4888

France

Novartis Pharma S.A.S.

Tél: +33 1 55 47 66 00

Portugal

Novartis Farma ‑ Pharmaceutical Products, S.A.

Tel: +351 21 000 8600

Croatia

Novartis Hrvatska d.o.o.

Tel. +385 1 6274 220

Romania

Novartis Pharma Services Romania SRL

Tel: +40 21 31299 01

Ireland

Novartis Ireland Limited

Tel: +353 1 260 12 55

Slovenia

Novartis Pharma Services Inc.

Tel: +386 1 300 75 50

Iceland

Vistor hf.

Tel: +354 535 7000

Slovak Republic

Novartis Slovakia s.r.o.

Tel: +421 2 5542 5439

Italy

Novartis Farma S.p.A.

Tel: +39 02 96 54 1

Finland/Suomi

Novartis Finland Oy

Puh/Tel: +358 (0)10 6133 200

Cyprus

Novartis Pharma Services Inc.

Tel: +357 22 690 690

Sweden

Novartis Sverige AB

Tel: +46 8 732 32 00

Latvia

Novartis Pharma Services Inc.

Tel: +371 67 887 070

United Kingdom

Novartis Pharmaceuticals UK Ltd.

Tel: +44 1276 698370

Date of the most recent review of this leaflet:

Other sources of information

Detailed information on this medicine is available on the website of the European Medicines Agency: http://www.ema.europa.eu

Instructions for use of the Seebri Breezhaler inhaler

Read the Instructions for Use completely before using Seebri Breezhaler

A hand presses an orange lever on a white medical device to activate the injection mechanism

Two hands hold a cylindrical white medical device with curved arrows indicating a rotational movement to the right and left

Technical drawing showing a hand pressing a circular medical device against the skin with an arrow indicating downward movement

White medical device with central orange button and two orange side knobs on a white background

Insert

Pierce and release

Breathe in deeply

Check that the capsule is empty

Gray downward-pointing arrow with the white number one centered at the top of the arrow shaft

Gray downward-pointing arrow with the white number two centered on a neutral background

Gray downward-pointing arrow with the word 'Comprobar' written in white at the top of the arrow shaftGray downward-pointing arrow with the white number 3 centered at the top

A hand lifts the white cap of a medical device above the orange and gray cylindrical base, indicated by a black arrow pointing upward

Two hands grip a cylindrical white medical device with black arrows indicating a squeezing motion toward the center

Line drawing of a profile face with arrows indicating movement of the jaw and tongue downward

White medical device with central orange button and two orange side knobs on a white background

Step 1a:

Remove the cap

Step 2a:

Pierce the capsule once only

Hold the inhaler in an upright position.

Pierce the capsule by pressing both buttons firmly at the same time.

Step 3a:

Breathe out fully

Do not blow into the inhaler.

Check that the capsule is empty

Open the inhaler to check if any powder remains in the capsule.

Two hands open a cylindrical medical device by rotating the upper part upward

You should hear a click when the capsule is pierced.

Pierce the capsule only once.

Technical drawing showing a hand pressing a medical device against the skin with a curved arrow indicating downward movement

If powder remains in the capsule:

Close the inhaler.

Repeat steps 3a to 3c.

Step 1b:

Open the inhaler

Two hands holding a white and orange medical device with black arrows indicating lateral rotational or opening movement

Step 2b:

Release the buttons completely

Step 3b:

Inhale the medicine deeply

Hold the inhaler as shown in the figure.

Place the mouthpiece in your mouth and close your lips tightly around it.

Do not press the buttons.

Powder remaining Empty

A medication blister pack with eight oval white compartments and a single separated tablet on a white background

Two hands opening a plastic blister pack to remove a single orange and brown capsule on a white background

Breathe in quickly and as deeply as possible.

During inhalation, you will hear a humming sound.

You may taste the medicine when inhaling.

A hand pressing the plunger of a medical device to expel a small orange cylindrical object downward

Step 1c:

Remove the capsule

Separate one blister from the blister strip.

Open the blister and remove one capsule.

Do not push the capsule through the foil.

Do not swallow the capsule.

Line drawing of a person's face and neck showing the jaw and throat area with simple lines on a white background

Step 3c:

Hold your breath

Hold your breath for 5 seconds.

Remove the empty capsule

Dispose of the empty capsule in your household waste.

Close the inhaler and replace the cap.

Illustration of a hand pressing the orange button of a medical device to activate the internal mechanism, indicated by a black arrow

Step 1d:

Insert the capsule

Never place the capsule directly into the mouthpiece.

Important information

  • Seebri Breezhaler capsules must always be kept in the blister and only removed immediately before use.
  • Do not push the capsule through the foil when removing it from the blister.
  • Do not swallow the capsule.
  • Do not use Seebri Breezhaler capsules with another inhaler.
  • Do not use the Seebri Breezhaler inhaler with another capsule medicine.
  • Never place the capsule in your mouth or into the inhaler mouthpiece.
  • Do not press the side buttons more than once.
  • Do not blow into the mouthpiece.
  • Do not press the buttons while inhaling through the mouthpiece.
  • Do not handle the capsules with wet hands.
  • Never wash your inhaler with water.

A hand lifting and rotating the white lid of an orange and white cylindrical container downward to open it

Step 1e:

Close the inhaler

Your Seebri Breezhaler package contains:

  • one Seebri Breezhaler inhaler
  • one or more blister strips, each containing 6 or 10 Seebri Breezhaler capsules for use with the inhaler

Black text on white background reading 'Paracapsular compartment'

Black text on white background displayed in two lines reading 'Lateral pushers'Three medical diagrams showing a cylindrical container, the opening mechanism of a device, and a pill blister pack with reference lines

Frequently asked questions

Why didn't the inhaler make a noise when I inhaled?

The capsule may be stuck in the chamber. If this happens, carefully release the capsule by tapping the base of the inhaler. Inhale the medicine again by repeating steps 3a to 3c.

What should I do if there is powder left inside the capsule?

You have not received enough of your medicine. Close the inhaler and repeat steps 3a to 3c.

I coughed after inhaling, is this important?

This may happen. If the capsule is empty, you have received enough of your medicine.

I noticed small fragments of the capsule on my tongue, is this important?

This may happen. It is not harmful. The likelihood of capsules fragmenting increases if the capsule is pierced more than once.

Cleaning the inhaler

Wipe the mouthpiece inside and outside with a clean, dry, lint-free cloth to remove any powder residue. Keep the inhaler dry. Never wash your inhaler with water.

Disposal of the inhaler after use

Each inhaler should be discarded after all capsules have been used. Ask your pharmacist how to dispose of medicines and inhalers that you no longer need.